Notice Number: NOT-OD-07-005

Key Dates
Release Date: October 13, 2006
Effective Date: October 13, 2006

Issued by
National Institutes of Health (NIH) (http://www.nih.gov)
National Human Genome Research Institute (NHGRI) (https://www.genome.gov)
National Institute of Mental Health (NIMH) (http://www.nimh.nih.gov)

This notice is to clarify that resubmission (amended) applications must be submitted when appropriate for the following recently released funding opportunity announcements:

Near-Term Technology Development for Genome Sequencing (R01)
RFA-HG-06-015

Near-Term Technology Development for Genome Sequencing (R21)
RFA-HG-06-016

Near-Term Technology Development for Genome Sequencing (R21/R33)
RFA-HG-06-017

Near-Term Technology Development for Genome Sequencing (SBIR [R43/R44])
RFA-HG-06-018

Near-Term Technology Development for Genome Sequencing (STTR [R41/R42])
RFA-HG-06-019

Revolutionary Genome Sequencing Technologies The $1000 Genome (R01)
RFA-HG-06-020

Revolutionary Genome Sequencing Technologies - The $1000 Genome (R21)
RFA-HG-06-021

Revolutionary Genome Sequencing Technologies The $1000 Genome (R21/R33)
RFA-HG-06-022

Revolutionary Genome Sequencing Technologies The $1000 Genome (SBIR [R43/R44])
RFA-HG-06-023

Revolutionary Genome Sequencing Technologies The $1000 Genome (STTR [R41/R42])
RFA-HG-06-024

Applicants may not simultaneously submit identical/essentially identical applications under more than one HHS funding opportunity announcement. If an application did not receive an award as a result of the previous Request for Applications, an application on the same topic that is being submitted to a corresponding reissued FOA mentioned above, must be prepared as a resubmission/amended version. Such an application must include an Introduction and mark the text to show changes. If a new application has been submitted for a standard submission date and the applicant would prefer to respond to the reissued Request for Applications, then the new application must be withdrawn prior to the submission of a resubmission application.

The following additional review criteria will be used when evaluating the scientific and technical merit of a resubmitted application:

1. Are the responses to comments from the previous scientific review group adequate?
2. Are the improvements in the resubmission application appropriate?

Inquiry

Inquiries regarding this Notice should be directed to:

Jeffery A. Schloss, Ph.D.
Division of Extramural Research
National Human Genome Research Institute, NIH
5635 Fishers Lane, Suite 4076
Bethesda, MD 20892-9305
Telephone: (301) 496-7531
Email: [email protected]